Literature DB >> 8599935

Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.

M K Webster1, D J Donoghue.   

Abstract

Achondroplasia, the most common genetic form of dwarfism, is an autosomal dominant disorder whose underlying mechanism is a defect in the maturation of the cartilage growth plate of long bones. Achondroplasia has recently been shown to result from a Gly to Arg substitution in the transmembrane domain of the fibroblast growth factor receptor 3 (FGFR3), although the molecular consequences of this mutation have not been investigated. By substituting the transmembrane domain of the Neu receptor tyrosine kinase with the transmembrane domains of wild-type and mutant FGFR3, the Arg380 mutation in FGFR3 is shown to activate both the kinase and transforming activities of this chimeric receptor. Residues with side chains capable of participating in hydrogen bond formation, including Glu, Asp, and to a lesser extent, Gln, His and Lys, were able to substitute for the activating Arg380 mutation. The Arg380 point mutation also causes ligand-independent stimulation of the tyrosine kinase activity of FGFR3 itself, and greatly increased constitutive levels of phosphotyrosine on the receptor. These results suggest that the molecular basis of achondroplasia is unregulated signal transduction through FGFR3, which may result in inappropriate cartilage growth plate differentiation and thus abnormal long bone development. Achondroplasia may be one of the number of cogenital disorders where constitutive activation of a member of the FGFR family leads to development abnormalities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599935      PMCID: PMC449970     

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  47 in total

1.  Substitution of the insulin receptor transmembrane domain with the c-neu/erbB2 transmembrane domain constitutively activates the insulin receptor kinase in vitro.

Authors:  K Yamada; E Goncalves; C R Kahn; S E Shoelson
Journal:  J Biol Chem       Date:  1992-06-25       Impact factor: 5.157

Review 2.  Signalling by receptor tyrosine kinases.

Authors:  W J Fantl; D E Johnson; L T Williams
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

3.  Substitution of the erbB-2 oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin and insulin-receptor substrate 1.

Authors:  B Cheatham; S E Shoelson; K Yamada; E Goncalves; C R Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

4.  SHC and GRB-2 are constitutively by an epidermal growth factor receptor with a point mutation in the transmembrane domain.

Authors:  M Miloso; M Mazzotti; W C Vass; L Beguinot
Journal:  J Biol Chem       Date:  1995-08-18       Impact factor: 5.157

Review 5.  Structural and functional diversity in the FGF receptor multigene family.

Authors:  D E Johnson; L T Williams
Journal:  Adv Cancer Res       Date:  1993       Impact factor: 6.242

6.  Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo.

Authors:  F J Lofts; H C Hurst; M J Sternberg; W J Gullick
Journal:  Oncogene       Date:  1993-10       Impact factor: 9.867

7.  Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis.

Authors:  K Peters; D Ornitz; S Werner; L Williams
Journal:  Dev Biol       Date:  1993-02       Impact factor: 3.582

8.  Molecular definition of the smallest region of deletion overlap in the Wolf-Hirschhorn syndrome.

Authors:  K Y Gandelman; L Gibson; M S Meyn; T L Yang-Feng
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

9.  Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein.

Authors:  W J Gullick; A C Bottomley; F J Lofts; D G Doak; D Mulvey; R Newman; M J Crumpton; M J Sternberg; I D Campbell
Journal:  EMBO J       Date:  1992-01       Impact factor: 11.598

10.  Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction.

Authors:  B A Lee; D J Donoghue
Journal:  J Cell Biol       Date:  1992-09       Impact factor: 10.539

View more
  81 in total

1.  Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase.

Authors:  C A Bell; J A Tynan; K C Hart; A N Meyer; S C Robertson; D J Donoghue
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

Review 2.  Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism.

Authors:  William A Horton; Gregory P Lunstrum
Journal:  Rev Endocr Metab Disord       Date:  2002-12       Impact factor: 6.514

Review 3.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

Review 4.  Single-spanning transmembrane domains in cell growth and cell-cell interactions: More than meets the eye?

Authors:  Pierre Hubert; Paul Sawma; Jean-Pierre Duneau; Jonathan Khao; Jérôme Hénin; Dominique Bagnard; James Sturgis
Journal:  Cell Adh Migr       Date:  2010-04-20       Impact factor: 3.405

5.  Typical achondroplasia secondary to a unique insertional variant of FGFR3 with in vitro demonstration of its effect on FGFR3 function.

Authors:  April N Meyer; Peggy Modaff; Clark G Wang; Elizabeth Wohler; Nara L Sobreira; Daniel J Donoghue; Richard M Pauli
Journal:  Am J Med Genet A       Date:  2020-12-02       Impact factor: 2.802

Review 6.  Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.

Authors:  Edwin Li; Kalina Hristova
Journal:  Biochemistry       Date:  2006-05-23       Impact factor: 3.162

7.  Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain.

Authors:  M K Webster; D J Donoghue
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

8.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

Authors:  M Chesi; E Nardini; L A Brents; E Schröck; T Ried; W M Kuehl; P L Bergsagel
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

Review 9.  Signaling and transcriptional regulation in osteoblast commitment and differentiation.

Authors:  Wei Huang; Shuying Yang; Jianzhong Shao; Yi-Ping Li
Journal:  Front Biosci       Date:  2007-05-01

Review 10.  FGFR3-related dwarfism and cell signaling.

Authors:  Daisuke Harada; Yoshitaka Yamanaka; Koso Ueda; Hiroyuki Tanaka; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2008-12-09       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.